Step therapy — sometimes called “fail first” — is the insurance practice of requiring a patient to try and fail one or more cheaper medications before the insurer will cover the drug their physician actually prescribed. On paper, it’s a cost-control tool that nudges everyone toward generics. In practice, for patients with serious conditions where drug response is highly individual, it’s a delay engine that demonstrably harms people. And when the harm happens, the insurer has structured the process so that no one is ever quite responsible.
This is not a fringe complaint. It’s a documented pattern across rheumatology, oncology, psychiatry, and neurology.
How the policy works in practice
Your doctor decides, based on your specific case, that a particular medication is the right starting therapy — say, a biologic for severe rheumatoid arthritis or a specific atypical antipsychotic for bipolar disorder. The pharmacy submits the prescription. The insurer denies coverage and informs you that you must first try Drug A, fail it for a defined period (often 30 to 90 days), and only then will Drug B be considered. If Drug A doesn’t work, you don’t go straight to your prescribed Drug B — you may be required to try Drug C next, and fail that too. Each step takes weeks or months. For a patient with progressive joint damage, untreated psychosis, or aggressive cancer, “weeks or months” is not an abstract delay.
The documented harm
Patient advocacy groups, the American Medical Association, and multiple state legislatures have collected case data on step therapy outcomes. The harms include irreversible disease progression in inflammatory arthritis, hospitalizations for psychiatric decompensation while patients cycle through medications they’ve already been told won’t work for them, delayed cancer treatment with measurable survival impact, and stroke and cardiac events in patients denied direct access to anticoagulants their cardiologists prescribed. A 2019 study in JAMA Network Open documented worse clinical outcomes for patients subjected to step therapy compared to direct access. The pattern is consistent: forcing failure produces failure, and some of those failures are permanent.
The accountability vacuum
Here’s the part that should bother people more than it does. When a patient is harmed by step therapy, no actor in the system absorbs responsibility. The insurer says they followed their published policy. The pharmacy benefit manager says they applied the formulary. The prescribing physician says they tried to override and was denied. The state insurance regulator says step therapy is legal. The patient or their estate has no clear cause of action because the insurer’s policy was disclosed and the harm wasn’t, in legal terms, “caused” by any single actor — it was caused by the structure. There is no malpractice claim against an insurer for medical decisions, because insurers officially don’t make medical decisions. They just determine what’s paid for.
The takeaway
Step therapy as currently practiced is a system that produces predictable, documented harm with no one bearing legal accountability for it. State-level “step therapy reform” laws have begun creating override pathways, but they’re inconsistent and easy to evade. Until the accountability gap is closed, patients and physicians have to fight every denial individually, and some lose the fight in ways that can’t be undone.
Leave a Reply